Phase 3 Readout~month

Phase 3 Topline: A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase 3 Clinical Trial to Evaluate the

Indication
Atopic Dermatitis

Other upcoming events for ACUT

Patent ExpiryPatent/Exclusivity Expiry: VYXEOS
Patent ExpiryPatent/Exclusivity Expiry: LUTATHERA

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
    Phase 3 Topline: A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase 3 Clinical Trial to Evaluate the — ACUT Phase 3 Readout | BioSniper